Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy
Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures....
Saved in:
Published in | Bone (New York, N.Y.) Vol. 52; no. 1; pp. 360 - 365 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier Inc
01.01.2013
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 8756-3282 1873-2763 1873-2763 |
DOI | 10.1016/j.bone.2012.10.006 |
Cover
Abstract | Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures.
A prospective study was conducted involving 14 consecutive patients presenting during 2years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6months after teriparatide.
Administration of 20μg of teriparatide subcutaneously daily for 6months to 5 of the 14 patients was associated with 2–3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality.
► Bisphosphonates suppress bone remodelling, which can lead to microdamage accumulation and atypical femoral fractures. ► Teriparatide given to five patients with atypical fractures was associated with an increase in bone remodelling markers and fracture healing. ► The volume of less densely and more heterogeneously mineralised bone increased and the proportion of older, more densely mineralised bone decreased. ► Teriparatide may assist in healing of atypical fractures and restoration of bone quality. |
---|---|
AbstractList | Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality.Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality. Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6months after teriparatide. Administration of 20 mu g of teriparatide subcutaneously daily for 6months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality. Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6months after teriparatide. Administration of 20μg of teriparatide subcutaneously daily for 6months to 5 of the 14 patients was associated with 2–3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality. ► Bisphosphonates suppress bone remodelling, which can lead to microdamage accumulation and atypical femoral fractures. ► Teriparatide given to five patients with atypical fractures was associated with an increase in bone remodelling markers and fracture healing. ► The volume of less densely and more heterogeneously mineralised bone increased and the proportion of older, more densely mineralised bone decreased. ► Teriparatide may assist in healing of atypical fractures and restoration of bone quality. Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality. Abstract Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2–3 fold increase in bone remodelling markers ( p = 0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% ( p = 0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% ( p = 0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality. |
Author | Hardidge, Andrew Chiang, Cherie Ying Iuliano-Burns, Sandra Ghasem-Zadeh, Ali Seeman, Ego Zebaze, Roger M.D. |
Author_xml | – sequence: 1 givenname: Cherie Ying surname: Chiang fullname: Chiang, Cherie Ying email: cherie@cheriechiang.com organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia – sequence: 2 givenname: Roger M.D. surname: Zebaze fullname: Zebaze, Roger M.D. email: zebaze@unimelb.edu.au organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia – sequence: 3 givenname: Ali surname: Ghasem-Zadeh fullname: Ghasem-Zadeh, Ali email: alig@unimelb.edu.au organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia – sequence: 4 givenname: Sandra surname: Iuliano-Burns fullname: Iuliano-Burns, Sandra email: sandraib@unimelb.edu.au organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia – sequence: 5 givenname: Andrew surname: Hardidge fullname: Hardidge, Andrew email: Andrew.HARDIDGE@austin.org.au organization: Department of Orthopaedic Surgery, Austin Health, University of Melbourne, Melbourne, Australia – sequence: 6 givenname: Ego surname: Seeman fullname: Seeman, Ego email: egos@unimelb.edu.au organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27153041$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23072919$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkl1rFDEUhoNU7Lb6B7yQ3AjezJqPmUlGRJBSP6DghfU6ZJKzbtbZyTTJVObfN2FXhYLVi3DC4XlPyPueM3Qy-hEQek7JmhLavt6t-9xYM0JZbqwJaR-hFZWCV0y0_AStpGjaijPJTtFZjDtCCO8EfYJOGSeCdbRboXgNwU066OQsYLefgr-FiMtgfDPrwaUF69HiLeT7-B37DdZpmZzRA97A3odSgzZpDlmmY_TG6QQW_3Rpi3sXp60vZ8xNnLYQ9LQ8RY83eojw7FjP0bcPl9cXn6qrLx8_X7y_qkzTdqmydWe5kEJSQ4zQjda95Qxq2cleMtmynrRcMACoLSdcSpBU09p2RGveNz0_R68Oc_OnbmaISe1dNDAMegQ_R0VZI0RDWdv8B8qorGXbkIy-OKJzvwerpuD2Oizql6cZeHkEdMw2ZXdG4-IfTtCGk5pmjh04E3yMATa_EUpUCVjtVMlBlYBLLwecRfKeyLiUw_NjCtoND0vfHqSQPb91EFQ0DkYD1gUwSVnvHpa_uyc3eSPKIvyABeLOz2HMaSqqIlNEfS3LV3aP5iGc8mLcm78P-Nfrd5Sk6fs |
CitedBy_id | crossref_primary_10_1007_s12018_017_9239_3 crossref_primary_10_1016_j_tcr_2017_10_014 crossref_primary_10_1016_j_beem_2014_09_003 crossref_primary_10_1016_j_jogc_2022_03_004 crossref_primary_10_4184_asj_2014_8_4_498 crossref_primary_10_1016_j_bonr_2020_100249 crossref_primary_10_4158_GL_2020_0524SUPPL crossref_primary_10_1097_BCO_0000000000000278 crossref_primary_10_1210_clinem_dgz295 crossref_primary_10_1186_s13256_015_0590_z crossref_primary_10_1148_rg_2015140301 crossref_primary_10_1016_j_jos_2017_10_008 crossref_primary_10_1007_s00198_021_05948_w crossref_primary_10_1016_j_bone_2020_115726 crossref_primary_10_1016_j_bonr_2017_01_002 crossref_primary_10_3928_01477447_20151020_16 crossref_primary_10_1007_s00198_023_06768_w crossref_primary_10_5794_jjoms_62_244 crossref_primary_10_1097_BOT_0000000000000851 crossref_primary_10_1016_j_semarthrit_2014_09_005 crossref_primary_10_1038_bonekey_2014_54 crossref_primary_10_1007_s11914_021_00696_6 crossref_primary_10_1016_j_jbo_2019_100259 crossref_primary_10_1177_2309499017727916 crossref_primary_10_4055_jkoa_2024_59_1_9 crossref_primary_10_1016_j_jcte_2016_05_004 crossref_primary_10_1259_bjr_20150725 crossref_primary_10_1517_14712598_2015_977249 crossref_primary_10_1097_BOR_0000000000000057 crossref_primary_10_15369_sujms_31_73 crossref_primary_10_1007_s13346_017_0394_3 crossref_primary_10_11005_jbm_2017_24_1_65 crossref_primary_10_5812_traumamon_42869 crossref_primary_10_2106_JBJS_RVW_N_00062 crossref_primary_10_1007_s00774_014_0617_3 crossref_primary_10_1007_s00198_018_4507_8 crossref_primary_10_1097_BOT_0000000000000743 crossref_primary_10_1055_s_0041_1740995 crossref_primary_10_1002_jbm4_10250 crossref_primary_10_1097_BOT_0000000000000508 crossref_primary_10_3390_children9020268 crossref_primary_10_1007_s00774_014_0606_6 crossref_primary_10_1016_j_bone_2019_08_006 crossref_primary_10_1177_21514593221090392 crossref_primary_10_1007_s00198_017_4155_4 crossref_primary_10_47671_10_47671_TVG_78_22_063 crossref_primary_10_1016_j_jogc_2021_09_013 crossref_primary_10_1007_s00402_023_05171_8 crossref_primary_10_1016_j_bone_2013_11_016 crossref_primary_10_1111_joa_12533 crossref_primary_10_1007_s13670_016_0161_1 crossref_primary_10_1080_24725625_2017_1361373 crossref_primary_10_1002_jbmr_1998 crossref_primary_10_1021_acs_biomac_7b00750 crossref_primary_10_1186_s13063_021_05556_3 crossref_primary_10_1080_14397595_2017_1362093 crossref_primary_10_1007_s00198_018_4658_7 crossref_primary_10_11005_jbm_2023_30_3_209 crossref_primary_10_1007_s00198_016_3513_y crossref_primary_10_11005_jbm_2020_27_3_167 crossref_primary_10_1530_EJE_17_1002 crossref_primary_10_17816_vto201320377_81 crossref_primary_10_4158_EP14315_OR crossref_primary_10_1007_s00198_015_3354_0 crossref_primary_10_1177_2210491720952444 crossref_primary_10_1016_j_jor_2017_01_002 crossref_primary_10_1016_j_jbo_2023_100478 crossref_primary_10_1007_s00223_024_01244_x crossref_primary_10_3390_bioengineering7010022 crossref_primary_10_4103_jbjd_jbjd_34_22 crossref_primary_10_1016_j_bonr_2014_10_004 crossref_primary_10_12671_jkfs_2018_31_4_159 crossref_primary_10_1186_1756_0500_6_11 crossref_primary_10_1016_j_bone_2015_06_017 crossref_primary_10_1007_s11914_019_00501_5 crossref_primary_10_1016_j_otsr_2022_103475 crossref_primary_10_3389_fsurg_2022_1063170 crossref_primary_10_1016_j_jecr_2017_12_002 crossref_primary_10_1007_s00198_015_3331_7 crossref_primary_10_1016_j_bone_2018_01_033 crossref_primary_10_13004_kjnt_2016_12_2_123 crossref_primary_10_3390_medicina60111814 crossref_primary_10_14260_jemds_2014_3586 crossref_primary_10_1002_jbm4_10387 crossref_primary_10_1007_s00590_016_1742_6 crossref_primary_10_1007_s13670_013_0045_6 crossref_primary_10_1155_2013_249872 crossref_primary_10_22159_ajpcr_2021_v14i11_43135 crossref_primary_10_1007_s00774_025_01589_9 crossref_primary_10_47671_TVG_78_22_063 crossref_primary_10_1016_j_bone_2020_115671 crossref_primary_10_1097_BOT_0000000000001116 crossref_primary_10_1002_jor_24953 crossref_primary_10_1016_j_bone_2013_01_007 crossref_primary_10_11005_jbm_2015_22_4_183 crossref_primary_10_4103_ortho_IJOrtho_315_17 crossref_primary_10_1007_s40520_013_0133_7 crossref_primary_10_1002_jbmr_2424 crossref_primary_10_1111_os_12307 crossref_primary_10_2106_JBJS_CC_15_00172 crossref_primary_10_1007_s00198_017_4286_7 crossref_primary_10_1097_01_med_0000436194_10599_94 crossref_primary_10_1302_0301_620X_99B3_BJJ_2016_1144_R1 crossref_primary_10_1186_s12891_017_1878_5 crossref_primary_10_1007_s13554_014_0013_5 crossref_primary_10_1007_s43465_022_00639_y crossref_primary_10_1007_s00256_016_2346_2 crossref_primary_10_1007_s00774_022_01378_8 crossref_primary_10_1007_s12603_015_0652_3 crossref_primary_10_1007_s11914_014_0239_7 |
Cites_doi | 10.1002/jor.21448 10.1359/jbmr.2000.15.4.613 10.3233/THC-1998-65-606 10.1007/s00198-008-0754-4 10.1002/jbmr.253 10.1359/jbmr.070609 10.1007/s00223-011-9500-6 10.1097/BOT.0b013e3181b6499b 10.1016/j.bone.2010.05.019 10.1056/NEJMoa1010650 10.1007/s00223-010-9360-5 10.2106/JBJS.J.01379 10.1359/JBMR.051109 10.1038/206489a0 10.1016/j.bone.2006.04.028 10.1007/s11999-011-1985-9 10.1016/j.bone.2007.11.011 10.1001/jama.2011.190 10.1210/jc.2011-0593 10.1002/jbmr.233 10.1359/jbmr.060314 10.1210/jc.2010-2520 10.1001/archinte.164.18.2024 10.1359/jbmr.090731 10.1056/NEJMra053077 10.1056/NEJMc1002684 10.1016/j.bone.2011.09.042 10.1002/jbmr.261 10.1016/j.bone.2004.07.016 10.1210/jc.2002-021988 10.1007/s11914-005-0004-z 10.1016/0021-9290(69)90036-0 |
ContentType | Journal Article |
Copyright | 2012 2014 INIST-CNRS Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2012 – notice: 2014 INIST-CNRS – notice: Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7QP |
DOI | 10.1016/j.bone.2012.10.006 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
DatabaseTitleList | MEDLINE - Academic Calcium & Calcified Tissue Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1873-2763 |
EndPage | 365 |
ExternalDocumentID | 23072919 27153041 10_1016_j_bone_2012_10_006 S8756328212013130 1_s2_0_S8756328212013130 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OF0 OR. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K WUQ X7M Z5R ZGI ZMT ~02 ~G- 1RT AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU DOVZS EFLBG LCYCR ZA5 AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD 7QP |
ID | FETCH-LOGICAL-c569t-d49d378781c0c7a5aabd32e4898b82862b06372eee4d30388e81a14d90aa3b5b3 |
IEDL.DBID | AIKHN |
ISSN | 8756-3282 1873-2763 |
IngestDate | Sat Sep 27 17:08:48 EDT 2025 Sat Sep 27 18:04:45 EDT 2025 Thu Apr 03 06:57:08 EDT 2025 Wed Apr 02 07:26:45 EDT 2025 Tue Jul 01 03:41:26 EDT 2025 Thu Apr 24 22:55:57 EDT 2025 Fri Feb 23 02:22:08 EST 2024 Sun Feb 23 10:18:48 EST 2025 Tue Aug 26 16:32:49 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | High resolution computed tomography Osteoporosis Bisphosphonates Atypical femur fractures Teriparatide Femur High resolution Antiosteoporotic Radiodiagnosis Diseases of the osteoarticular system Fracture Trauma Treatment Antiosteoclastic agent Morphology Quality Medical imagery Atypical Computerized axial tomography Bone Cicatrization |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c569t-d49d378781c0c7a5aabd32e4898b82862b06372eee4d30388e81a14d90aa3b5b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
OpenAccessLink | http://hdl.handle.net/11343/41859 |
PMID | 23072919 |
PQID | 1221848650 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1257751265 proquest_miscellaneous_1221848650 pubmed_primary_23072919 pascalfrancis_primary_27153041 crossref_primary_10_1016_j_bone_2012_10_006 crossref_citationtrail_10_1016_j_bone_2012_10_006 elsevier_sciencedirect_doi_10_1016_j_bone_2012_10_006 elsevier_clinicalkeyesjournals_1_s2_0_S8756328212013130 elsevier_clinicalkey_doi_10_1016_j_bone_2012_10_006 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-01-01 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Amsterdam |
PublicationPlace_xml | – name: Amsterdam – name: United States |
PublicationTitle | Bone (New York, N.Y.) |
PublicationTitleAlternate | Bone |
PublicationYear | 2013 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Seeman (bb0015) 2010; 25 Currey (bb0020) 2005; 3 Cheung, Seeman (bb0075) 2010; 363 Yeni, Zelman, Divine, Kim, Fyhrie (bb0105) 2008; 42 Lindsay, Scheele, Neer, Pohl, Adami, Mautalen, Reginster, Stepan, Myers, Mitlak (bb0050) 2004; 164 Jobke, Muche, Burghardt, Semler, Link, Majumdar (bb0150) 2011; 89 Currey (bb0115) 1969; 2 Hattner, Epker, Frost (bb0005) 1965; 206 Mashiba, Hirano, Turner, Forwood, Johnston, Burr (bb0130) 2000; 15 Tang, Allen, Phipps, Burr, Vashishth (bb0110) 2009; 20 Lindsay, Cosman, Zhou, Bostrom, Shen, Cruz, Nieves, Dempster (bb0160) 2006; 21 Schilcher, Michaelsson, Aspenberg (bb0090) 2011; 364 Giusti, Hamdy, Papapoulos (bb0100) 2010; 47 Karim, Vashishth (bb0025) 2011; 29 Chapurlat, Arlot, Burt-Pichat, Chavassieux, Roux, Portero-Muzy, Delmas (bb0140) 2007; 22 Shane, Burr, Ebeling, Abrahamsen, Adler, Brown, Cheung, Cosman, Curtis, Dell, Dempster, Einhorn, Genant, Geusens, Klaushofer, Koval, Lane, McKiernan, McKinney, Ng, Nieves, O'Keefe, Papapoulos, Sen, Van der Meulen, Weinstein, Whyte (bb0035) 2010; 25 Park-Wyllie, Mamdani, Juurlink, Hawker, Gunraj, Austin, Whelan, Weiler, Laupacis (bb0045) 2011; 305 Misof, Roschger, Cosman, Kurland, Tesch, Messmer, Dempster, Nieves, Shane, Fratzl, Klaushofer, Bilezikian, Lindsay (bb0170) 2003; 88 Wang, Bhattacharyya (bb0095) 2011; 26 Allen, Iwata, Phipps, Burr (bb0135) 2006; 39 Laib, Hauselmann, Ruegsegger (bb0080) 1998; 6 Ellegaard, Jorgensen, Schwarz (bb0145) 2010; 87 Peichl, Holzer, Maier, Holzer (bb0055) 2011; 93 Gomberg, Wustrack, Napoli, Arnaud, Black (bb0065) 2011; 96 Zebaze, GhasemZadeh, Seeman (bb0085) 2011 Currey (bb0030) 2005; 5 Carvalho, Voss, Almeida, Salgado, Bandeira (bb0070) 2011; 96 Aspenberg, Genant, Johansson, Nino, See, Krohn, García-Hernández, Recknor, Einhorn, Dalsky, Mitlak, Fierlinger, Lakshmanan (bb0060) 2010; 25 Seeman, Delmas (bb0010) 2006; 354 Ma, Zeng, Donley, Ste-Marie, Gallagher, Dalsky, Marcus, Eriksen (bb0155) 2006; 21 Koh, Goh, Png, Kwek, Howe (bb0040) 2010; 24 Nalla, Kruzic, Kinney, Ritchie (bb0120) 2004; 35 Unnanuntana, Ashfaq, Ton, Kleimeyer, Lane (bb0165) 2012; 470 Tjhia, Odvina, Rao, Stover, Wang, Fyhrie (bb0125) 2011; 49 Cheung (10.1016/j.bone.2012.10.006_bb0075) 2010; 363 Mashiba (10.1016/j.bone.2012.10.006_bb0130) 2000; 15 Tang (10.1016/j.bone.2012.10.006_bb0110) 2009; 20 Jobke (10.1016/j.bone.2012.10.006_bb0150) 2011; 89 Wang (10.1016/j.bone.2012.10.006_bb0095) 2011; 26 Unnanuntana (10.1016/j.bone.2012.10.006_bb0165) 2012; 470 Zebaze (10.1016/j.bone.2012.10.006_bb0085) 2011 Chapurlat (10.1016/j.bone.2012.10.006_bb0140) 2007; 22 Ma (10.1016/j.bone.2012.10.006_bb0155) 2006; 21 Gomberg (10.1016/j.bone.2012.10.006_bb0065) 2011; 96 Nalla (10.1016/j.bone.2012.10.006_bb0120) 2004; 35 Lindsay (10.1016/j.bone.2012.10.006_bb0160) 2006; 21 Aspenberg (10.1016/j.bone.2012.10.006_bb0060) 2010; 25 Karim (10.1016/j.bone.2012.10.006_bb0025) 2011; 29 Carvalho (10.1016/j.bone.2012.10.006_bb0070) 2011; 96 Allen (10.1016/j.bone.2012.10.006_bb0135) 2006; 39 Park-Wyllie (10.1016/j.bone.2012.10.006_bb0045) 2011; 305 Misof (10.1016/j.bone.2012.10.006_bb0170) 2003; 88 Ellegaard (10.1016/j.bone.2012.10.006_bb0145) 2010; 87 Shane (10.1016/j.bone.2012.10.006_bb0035) 2010; 25 Currey (10.1016/j.bone.2012.10.006_bb0115) 1969; 2 Giusti (10.1016/j.bone.2012.10.006_bb0100) 2010; 47 Hattner (10.1016/j.bone.2012.10.006_bb0005) 1965; 206 Tjhia (10.1016/j.bone.2012.10.006_bb0125) 2011; 49 Seeman (10.1016/j.bone.2012.10.006_bb0015) 2010; 25 Currey (10.1016/j.bone.2012.10.006_bb0020) 2005; 3 Peichl (10.1016/j.bone.2012.10.006_bb0055) 2011; 93 Yeni (10.1016/j.bone.2012.10.006_bb0105) 2008; 42 Lindsay (10.1016/j.bone.2012.10.006_bb0050) 2004; 164 Koh (10.1016/j.bone.2012.10.006_bb0040) 2010; 24 Currey (10.1016/j.bone.2012.10.006_bb0030) 2005; 5 Schilcher (10.1016/j.bone.2012.10.006_bb0090) 2011; 364 Laib (10.1016/j.bone.2012.10.006_bb0080) 1998; 6 Seeman (10.1016/j.bone.2012.10.006_bb0010) 2006; 354 |
References_xml | – volume: 88 start-page: 1150 year: 2003 end-page: 1156 ident: bb0170 article-title: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment publication-title: J Clin Endocrinol Metab – volume: 25 start-page: 2267 year: 2010 end-page: 2294 ident: bb0035 article-title: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research publication-title: J Bone Miner Res – volume: 2 start-page: 1 year: 1969 end-page: 11 ident: bb0115 article-title: The mechanical consequences of variation in the mineral content of bone publication-title: J Biomech – volume: 35 start-page: 1240 year: 2004 end-page: 1246 ident: bb0120 article-title: Effect of aging on the toughness of human cortical bone: evaluation by R-curves publication-title: Bone – volume: 29 start-page: 1 year: 2011 end-page: 6 ident: bb0025 article-title: Role of trabecular microarchitecture in the formation, accumulation, and morphology of microdamage in human cancellous bone publication-title: J Orthop Res – volume: 47 start-page: 169 year: 2010 end-page: 180 ident: bb0100 article-title: Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies publication-title: Bone – volume: 22 start-page: 1502 year: 2007 end-page: 1509 ident: bb0140 article-title: Microcrack frequency and bone remodelling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study publication-title: J Bone Miner Res – volume: 164 start-page: 2024 year: 2004 end-page: 2030 ident: bb0050 article-title: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis publication-title: Arch Intern Med – volume: 21 start-page: 855 year: 2006 end-page: 864 ident: bb0155 article-title: Teriparatide increases bone formation in modeling and remodelling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis publication-title: J Bone Miner Res – volume: 25 start-page: 404 year: 2010 end-page: 414 ident: bb0060 article-title: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures publication-title: J Bone Miner Res – volume: 87 start-page: 1 year: 2010 end-page: 13 ident: bb0145 article-title: Parathyroid hormone and bone healing publication-title: Calcif Tissue Int – volume: 470 start-page: 291 year: 2012 end-page: 298 ident: bb0165 article-title: The effect of long-term alendronate treatment on cortical thickness of the proximal femur publication-title: Clin Orthop Relat Res – volume: 6 start-page: 329 year: 1998 end-page: 337 ident: bb0080 article-title: In vivo high resolution 3D-QCT of the human forearm publication-title: Technol Health Care – volume: 15 start-page: 613 year: 2000 end-page: 620 ident: bb0130 article-title: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib publication-title: J Bone Miner Res – volume: 93 start-page: 1583 year: 2011 end-page: 1587 ident: bb0055 article-title: Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women publication-title: J Bone Joint Surg – volume: 42 start-page: 591 year: 2008 end-page: 596 ident: bb0105 article-title: Trabecular shear stress amplification and variability in human vertebral cancellous bone: relationship with age, gender, spine level and trabecular architecture publication-title: Bone – volume: 26 start-page: 553 year: 2011 end-page: 560 ident: bb0095 article-title: Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007 publication-title: J Bone Miner Res – volume: 354 start-page: 2250 year: 2006 end-page: 2261 ident: bb0010 article-title: Bone quality–the material and structural basis of bone strength and fragility publication-title: N Engl J Med – volume: 25 start-page: 2553 year: 2010 end-page: 2557 ident: bb0015 article-title: Bone morphology in response to alendronate as seen by high-resolution computed tomography: through a glass darkly publication-title: J Bone Miner Res – volume: 24 start-page: 75 year: 2010 end-page: 81 ident: bb0040 article-title: Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? publication-title: J Orthop Trauma – volume: 206 start-page: 489 year: 1965 end-page: 490 ident: bb0005 article-title: Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling publication-title: Nature – volume: 305 start-page: 783 year: 2011 end-page: 789 ident: bb0045 article-title: Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women publication-title: JAMA – volume: 364 start-page: 1728 year: 2011 end-page: 1737 ident: bb0090 article-title: Bisphosphonate use and atypical fractures of the femoral shaft publication-title: N Engl J Med – volume: 363 start-page: 2473 year: 2010 end-page: 2474 ident: bb0075 article-title: Teriparatide therapy for alendronate-associated osteonecrosis of the jaw publication-title: N Engl J Med – volume: 96 start-page: 2675 year: 2011 end-page: 2680 ident: bb0070 article-title: Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide publication-title: J Clin Endocrinol Metab – volume: 49 start-page: 1279 year: 2011 end-page: 1289 ident: bb0125 article-title: Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects publication-title: Bone – volume: 3 start-page: 52 year: 2005 end-page: 56 ident: bb0020 article-title: Bone architecture and fracture publication-title: Curr Osteoporos Rep – volume: 5 start-page: 317 year: 2005 ident: bb0030 article-title: Structural heterogeneity in bone: good or bad? publication-title: J Musculoskelet Neuronal Interact – volume: 96 start-page: 1627 year: 2011 end-page: 1632 ident: bb0065 article-title: Teriparatide, vitamin d, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy publication-title: J Clin Endocrinol Metab – year: 2011 ident: bb0085 article-title: A method and system for analysis of selected tissues – volume: 89 start-page: 130 year: 2011 end-page: 139 ident: bb0150 article-title: Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months publication-title: Calcif Tissue Int – volume: 20 start-page: 887 year: 2009 end-page: 894 ident: bb0110 article-title: Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate publication-title: Osteoporos Int – volume: 39 start-page: 872 year: 2006 end-page: 879 ident: bb0135 article-title: Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate publication-title: Bone – volume: 21 start-page: 366 year: 2006 end-page: 373 ident: bb0160 article-title: A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide publication-title: J Bone Miner Res – volume: 29 start-page: 1 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0025 article-title: Role of trabecular microarchitecture in the formation, accumulation, and morphology of microdamage in human cancellous bone publication-title: J Orthop Res doi: 10.1002/jor.21448 – volume: 15 start-page: 613 year: 2000 ident: 10.1016/j.bone.2012.10.006_bb0130 article-title: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib publication-title: J Bone Miner Res doi: 10.1359/jbmr.2000.15.4.613 – volume: 6 start-page: 329 year: 1998 ident: 10.1016/j.bone.2012.10.006_bb0080 article-title: In vivo high resolution 3D-QCT of the human forearm publication-title: Technol Health Care doi: 10.3233/THC-1998-65-606 – volume: 20 start-page: 887 year: 2009 ident: 10.1016/j.bone.2012.10.006_bb0110 article-title: Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate publication-title: Osteoporos Int doi: 10.1007/s00198-008-0754-4 – volume: 25 start-page: 2267 year: 2010 ident: 10.1016/j.bone.2012.10.006_bb0035 article-title: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research publication-title: J Bone Miner Res doi: 10.1002/jbmr.253 – volume: 22 start-page: 1502 year: 2007 ident: 10.1016/j.bone.2012.10.006_bb0140 article-title: Microcrack frequency and bone remodelling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study publication-title: J Bone Miner Res doi: 10.1359/jbmr.070609 – volume: 89 start-page: 130 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0150 article-title: Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months publication-title: Calcif Tissue Int doi: 10.1007/s00223-011-9500-6 – volume: 24 start-page: 75 year: 2010 ident: 10.1016/j.bone.2012.10.006_bb0040 article-title: Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? publication-title: J Orthop Trauma doi: 10.1097/BOT.0b013e3181b6499b – volume: 47 start-page: 169 year: 2010 ident: 10.1016/j.bone.2012.10.006_bb0100 article-title: Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies publication-title: Bone doi: 10.1016/j.bone.2010.05.019 – volume: 364 start-page: 1728 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0090 article-title: Bisphosphonate use and atypical fractures of the femoral shaft publication-title: N Engl J Med doi: 10.1056/NEJMoa1010650 – volume: 87 start-page: 1 year: 2010 ident: 10.1016/j.bone.2012.10.006_bb0145 article-title: Parathyroid hormone and bone healing publication-title: Calcif Tissue Int doi: 10.1007/s00223-010-9360-5 – volume: 93 start-page: 1583 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0055 article-title: Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women publication-title: J Bone Joint Surg doi: 10.2106/JBJS.J.01379 – volume: 21 start-page: 366 year: 2006 ident: 10.1016/j.bone.2012.10.006_bb0160 article-title: A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide publication-title: J Bone Miner Res doi: 10.1359/JBMR.051109 – volume: 206 start-page: 489 year: 1965 ident: 10.1016/j.bone.2012.10.006_bb0005 article-title: Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling publication-title: Nature doi: 10.1038/206489a0 – volume: 39 start-page: 872 year: 2006 ident: 10.1016/j.bone.2012.10.006_bb0135 article-title: Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate publication-title: Bone doi: 10.1016/j.bone.2006.04.028 – volume: 470 start-page: 291 year: 2012 ident: 10.1016/j.bone.2012.10.006_bb0165 article-title: The effect of long-term alendronate treatment on cortical thickness of the proximal femur publication-title: Clin Orthop Relat Res doi: 10.1007/s11999-011-1985-9 – volume: 42 start-page: 591 year: 2008 ident: 10.1016/j.bone.2012.10.006_bb0105 article-title: Trabecular shear stress amplification and variability in human vertebral cancellous bone: relationship with age, gender, spine level and trabecular architecture publication-title: Bone doi: 10.1016/j.bone.2007.11.011 – volume: 305 start-page: 783 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0045 article-title: Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women publication-title: JAMA doi: 10.1001/jama.2011.190 – volume: 96 start-page: 2675 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0070 article-title: Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2011-0593 – volume: 26 start-page: 553 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0095 article-title: Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007 publication-title: J Bone Miner Res doi: 10.1002/jbmr.233 – volume: 21 start-page: 855 year: 2006 ident: 10.1016/j.bone.2012.10.006_bb0155 article-title: Teriparatide increases bone formation in modeling and remodelling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis publication-title: J Bone Miner Res doi: 10.1359/jbmr.060314 – volume: 96 start-page: 1627 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0065 article-title: Teriparatide, vitamin d, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2010-2520 – volume: 5 start-page: 317 year: 2005 ident: 10.1016/j.bone.2012.10.006_bb0030 article-title: Structural heterogeneity in bone: good or bad? publication-title: J Musculoskelet Neuronal Interact – volume: 164 start-page: 2024 year: 2004 ident: 10.1016/j.bone.2012.10.006_bb0050 article-title: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis publication-title: Arch Intern Med doi: 10.1001/archinte.164.18.2024 – volume: 25 start-page: 404 year: 2010 ident: 10.1016/j.bone.2012.10.006_bb0060 article-title: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures publication-title: J Bone Miner Res doi: 10.1359/jbmr.090731 – volume: 354 start-page: 2250 year: 2006 ident: 10.1016/j.bone.2012.10.006_bb0010 article-title: Bone quality–the material and structural basis of bone strength and fragility publication-title: N Engl J Med doi: 10.1056/NEJMra053077 – volume: 363 start-page: 2473 year: 2010 ident: 10.1016/j.bone.2012.10.006_bb0075 article-title: Teriparatide therapy for alendronate-associated osteonecrosis of the jaw publication-title: N Engl J Med doi: 10.1056/NEJMc1002684 – volume: 49 start-page: 1279 year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0125 article-title: Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects publication-title: Bone doi: 10.1016/j.bone.2011.09.042 – volume: 25 start-page: 2553 year: 2010 ident: 10.1016/j.bone.2012.10.006_bb0015 article-title: Bone morphology in response to alendronate as seen by high-resolution computed tomography: through a glass darkly publication-title: J Bone Miner Res doi: 10.1002/jbmr.261 – volume: 35 start-page: 1240 year: 2004 ident: 10.1016/j.bone.2012.10.006_bb0120 article-title: Effect of aging on the toughness of human cortical bone: evaluation by R-curves publication-title: Bone doi: 10.1016/j.bone.2004.07.016 – volume: 88 start-page: 1150 year: 2003 ident: 10.1016/j.bone.2012.10.006_bb0170 article-title: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2002-021988 – year: 2011 ident: 10.1016/j.bone.2012.10.006_bb0085 – volume: 3 start-page: 52 year: 2005 ident: 10.1016/j.bone.2012.10.006_bb0020 article-title: Bone architecture and fracture publication-title: Curr Osteoporos Rep doi: 10.1007/s11914-005-0004-z – volume: 2 start-page: 1 year: 1969 ident: 10.1016/j.bone.2012.10.006_bb0115 article-title: The mechanical consequences of variation in the mineral content of bone publication-title: J Biomech doi: 10.1016/0021-9290(69)90036-0 |
SSID | ssj0003971 |
Score | 2.4422855 |
Snippet | Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when... Abstract Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone,... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 360 |
SubjectTerms | Aged Atypical femur fractures Biological and medical sciences Bisphosphonates Bone (cortical) Bone density Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use Bone healing Bone loss Bone remodelling Bones, joints and connective tissue. Antiinflammatory agents Computed tomography Computer programs Diphosphonates - adverse effects Female Femoral Fractures - chemically induced Femur Fracture Healing - drug effects Fractures Fundamental and applied biological sciences. Psychology High resolution computed tomography Humans Injuries of the limb. Injuries of the spine Male Medical sciences Mineralization Orthopedics Osteoporosis Pain Parathyroid hormone Pharmacology. Drug treatments Prospective Studies Radius Sex software Teriparatide Teriparatide - pharmacology Teriparatide - therapeutic use Tibia Traumas. Diseases due to physical agents Vertebrates: anatomy and physiology, studies on body, several organs or systems |
Title | Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S8756328212013130 https://www.clinicalkey.es/playcontent/1-s2.0-S8756328212013130 https://dx.doi.org/10.1016/j.bone.2012.10.006 https://www.ncbi.nlm.nih.gov/pubmed/23072919 https://www.proquest.com/docview/1221848650 https://www.proquest.com/docview/1257751265 |
Volume | 52 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1di9QwcDj3QAQRvfNj_VgiiC_S203SNu3jcnisyt2Ld3BvIWlSXNFusbsP--Jvd6ZJVw69FXwohdBpppnJfHVmAvBGWlmiYjUJd84kaW5MYnhdJxU1c0tVXVtHtcPnF_niKv14nV0fwOlQC0NplVH2B5neS-s4Mo2rOW2Xy-lntLRziR4DF9QzRqLffihQ2xcjOJx_-LS42AlkVLk8hPnyhABi7UxI87KrhrplcnESkrxu00_3W9PhqtXhuIvb7dFeL509hAfRoGTzgPMjOPDNERzPG3Smv2_ZW9anePax8yO4ex7_pB9Dd4msF_p-O8-WfWjBd4zwZKHQcstM4xgZkqjd2KpmZr1tiaSspuxculOF1Qb9dWYikb1jFNhldtm1X1Z0IR6ehSKv7WO4Ont_ebpI4gEMSZXl5Tpxaekk7uiCV7NKmcwY66TwaVEWlsrPhUUDRwnvfeoktZXxBTc8deXMGGkzK5_AqEG8nwFz3nF8R-GKskod-lwmy31hUuXLrFZGjYEPy66r2J2cDsn4poc0tK-alkATqWgMSTWGdzuYNvTm2Pu0HKiph6pTlJMaVcdeKPU3KN_Frd5prjuhZ_oPdhxDtoO8wdH_nHFyg9V2nyYUaqdZysfweuA9jbKAfvCYxq82iIogh71Ao3vfM5lSaOXl2RieBsb9PYOkPvK8fP6fqL-Ae6I_LYQiVC9htP6x8a_QZlvbCdw5-ckncWf-AqzLQYM |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1da9sw8CgpbIMxtnYf3kenwdjL8BJZsmU_hrKSrk1elkLfhGzJNGNzwpw85N_vzpIzytYM9mAMxmefdaf78n0AvBelKFCxmphba2KZGRMbXtdxRc3cpKrr0lLt8HSWTa7kl-v0-gBO-1oYSqsMst_L9E5ahyvDsJrD1WIx_IqWdibQY-AJ9YwR6LcfShpqPYDD8fnFZLYTyKhyuQ_zZTEBhNoZn-ZVLhvqlsmTTz7J6y799HBlWly12o-7uNse7fTS2WN4FAxKNvY4P4ED1xzB8bhBZ_rHln1gXYpnFzs_gnvT8Cf9GNo5sp7v-20dW3ShBdcywpP5QsstM41lZEiidmPLmpn1dkUkZTVl59KZKqw26K8zE4jsLKPALisX7epmSQfi4Zgv8to-hauzz_PTSRwGMMRVmhXr2MrCCtzROa9GlTKpMaUViZN5kZdUfp6UaOCoxDknraC2Mi7nhktbjIwRZVqKZzBoEO8XwKyzHJ-R27yopEWfy6SZy41UrkhrZVQEvF92XYXu5DQk47vu09C-aVoCTaSia0iqCD7uYFa-N8feu0VPTd1XnaKc1Kg69kKpv0G5Nmz1VnPdJnqk_2DHCNId5C2O_ucbT26x2u7TEoXaaSR5BO963tMoC-gHj2nccoOoJOSw52h077snVQqtvCyN4Lln3N9vENRHnhcv_xP1t3B_Mp9e6svz2cUreJB0k0MoWvUaBuufG_cG7bd1eRL25y85O0Np |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Teriparatide+improves+bone+quality+and+healing+of+atypical+femoral+fractures+associated+with+bisphosphonate+therapy&rft.jtitle=Bone+%28New+York%2C+N.Y.%29&rft.au=Chiang%2C+Cherie+Ying&rft.au=Zebaze%2C+Roger+M.D.&rft.au=Ghasem-Zadeh%2C+Ali&rft.au=Iuliano-Burns%2C+Sandra&rft.date=2013-01-01&rft.pub=Elsevier+Inc&rft.issn=8756-3282&rft.eissn=1873-2763&rft.volume=52&rft.issue=1&rft.spage=360&rft.epage=365&rft_id=info:doi/10.1016%2Fj.bone.2012.10.006&rft.externalDocID=S8756328212013130 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F87563282%2FS8756328212X00140%2Fcov150h.gif |